4.8 Article

Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination

Journal

BIOMATERIALS
Volume 150, Issue -, Pages 162-170

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2017.09.033

Keywords

Messenger RNA vaccine; Double stranded RNA; Immunostimulatory adjuvant; Pattern recognition receptor

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [15k20962, 25000006, 24300170, 15H03017]
  2. Center of Innovation Program (COI) from MEXT
  3. Funding Program for World Leading Innovative R&D on Science and Technology (FIRST Program) from the Japan Society for the Promotion of Science (JSPS)
  4. JSPS Core-to-Core Program
  5. A. Advanced Research Networks
  6. Uehara Memorial Foundation
  7. Takeda Science Foundation
  8. Grants-in-Aid for Scientific Research [15K20962, 17K20086] Funding Source: KAKEN

Ask authors/readers for more resources

Messenger (m)RNA vaccines require a safe and potent immunostimulatory adjuvant. In this study, we introduced immunostimulatory properties directly into mRNA molecules by hybridizing them with complementary RNA to create highly immunogenic double stranded (ds)RNAs. These dsRNA formulations, comprised entirely of RNA, are expected to be safe and highly efficient due to antigen expression and immunostimulation occurring simultaneously in the same antigen presenting cells. In this strategy, design of dsRNA is important. Indeed, hybridization using full-length antisense (as)RNA drastically reduced translational efficiency. In contrast, by limiting the hybridized portion to the mRNA poly A region, efficient translation and intense immunostimulation was simultaneously obtained. The immune response to the poly U-hybridized mRNAs (mRNA:pU) was mediated through Toll-like receptor (TLR)-3 and retinoic acid-inducible gene (RIG)-I. We also demonstrated that mRNA:pU activation of mouse and human dendritic cells was significantly more effective than activation using single stranded mRNA. In vivo mouse immunization 'experiments using ovalbumin showed that mRNA:pU significantly enhanced the intensity of specific cellular and humoral immune responses, compared to single stranded mRNA. Our novel mRNA:pU formulation can be delivered using a variety of mRNA carriers depending on the purpose and delivery route, providing a versatile platform for improving mRNA vaccine efficiency. (C) 2017 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available